Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BNP7787 also known as Tavocept, LP-300, Tavocept, Dimesna
BNP7787 · 2 trials · 5 indications
Number of days or months from the date of randomization to the earliest of the documented disease progression based on the Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 criteria
Number of days or months between the randomization date and the date of death from all causes
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Tavocept (BNP7787) |
| 2 | PLACEBO_COMPARATOR | 0.9% Sodium Chloride Soln. |
| LP-300 in Combination with Pemetrexed and Carboplatin | EXPERIMENTAL | LP-300 (investigational drug) + Pemetrexed and Carboplatin (standard of care chemotherapies) Dosing occurs on Day 1 of a 21-day cycle. |
| Pemetrexed and Carboplatin (Standard of Care) | ACTIVE_COMPARATOR | Pemetrexed and Carboplatin Only (standard of care chemotherapies) Dosing occurs on Day 1 of a 21-day cycle. |
| Name | Type | Description |
|---|---|---|
| BNP7787 | DRUG | The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks. |
| Placebo | DRUG | The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks. |
| LP-300 | DRUG | LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion. |
| Pemetrexed | DRUG | Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion. |
| Carboplatin | DRUG | Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion. |
INCLUSION CRITERIA Histologically or cytologically documented metastatic breast cancer Measurable disease Performance Status; ECOG 0-2 More than 2 weeks since prior radiation therapy 14 days or more since prior therapy and recovered from all side effects For patients who progress while receivi...
BNP7787 is an investigational small molecule developed by Lantern Pharma Inc. (ticker LTRN) for use in breast neoplasms. It was studied as a preventive treatment given to metastatic breast cancer patients receiving weekly paclitaxel, with the goal of reducing neurotoxicity associated with that chemotherapy. It is not described as an approved product.
BNP7787 was evaluated for the prevention of neurotoxicity in patients with metastatic breast cancer who were receiving weekly paclitaxel. The Phase 3 study enrolled 764 female patients aged 18 years and older with breast neoplasms and metastases. Its intended role was supportive, given alongside chemotherapy rather than as a direct antitumor agent.
BNP7787 is developed by Lantern Pharma Inc., which trades under the ticker LTRN. The company is the sponsor associated with the clinical program for this small molecule in breast neoplasms.
BNP7787 has been studied in a Phase 3 clinical trial. That trial is listed as completed, and no active trials are currently recorded for the program. The drug is investigational and is not described as FDA approved.
BNP7787 has been studied in one registered clinical trial, NCT00039780, titled Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel. It was a Phase 3, randomized, double-blind, placebo-controlled study that enrolled 764 female participants and is now completed.
The BNP7787 Phase 3 trial, NCT00039780, was a randomized, double-blind, placebo-controlled study in metastatic breast cancer patients receiving weekly paclitaxel. It enrolled 764 participants, all female and at least 18 years old, and evaluated BNP7787 for the prevention of neurotoxicity. The study is listed as completed.